Literature DB >> 10415870

Immunological escape mechanisms in pancreatic carcinoma.

H Ungefroren1, M Voss, W V Bernstorff, A Schmid, B Kremer, H Kalthoff.   

Abstract

Malignancies have developed several strategies to evade immune surveillance. We have investigated pancreatic cancer cell lines and pancreatic cancer surgical specimens to evaluate possibilities of tumor escape in the Fas system, and local immune suppression. Despite Fas expression the majority of cell lines was resistant to Fas-mediated apoptosis. The Fas-associated phosphatase-1 is a strong candidate to confer Fas resistance in pancreatic cancer cells. In addition, all investigated pancreatic cancer cell lines and cancer specimens expressed Fas ligand. Fas ligand was functional in cancer cell lines as shown by coculture assays of pancreatic cancer cell lines with Jurkat cells as targets. Additional local immune suppression was demonstrated by loss of T-cell receptor/CD3-zeta chain of pancreatic cancer infiltrating T-lymphocytes. We conclude that these tumor escape mechanisms may contribute to the poor prognosis of pancreatic cancer but also represent targets for new treatment modalities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415870     DOI: 10.1111/j.1749-6632.1999.tb09529.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Authors:  P Goedegebuure; J B Mitchem; M R Porembka; M C B Tan; B A Belt; A Wang-Gillam; W E Gillanders; W G Hawkins; D C Linehan
Journal:  Curr Cancer Drug Targets       Date:  2011-07       Impact factor: 3.428

3.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

4.  Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis.

Authors:  Felix Rückert; Gihan Dawelbait; Christof Winter; Arndt Hartmann; Axel Denz; Ole Ammerpohl; Michael Schroeder; Hans Konrad Schackert; Bence Sipos; Günter Klöppel; Holger Kalthoff; Hans-Detlev Saeger; Christian Pilarsky; Robert Grützmann
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

5.  Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells.

Authors:  Justin Hasenkamp; Andrea Borgerding; Gerald Wulf; Norbert Schmitz; Lorenz Truemper; Bertram Glass
Journal:  Ann Hematol       Date:  2009-10-13       Impact factor: 3.673

6.  Immunohistochemical analysis of cytokines and apoptosis in tuberculous lymphadenitis.

Authors:  Tehmina Mustafa; Stanley J Mogga; Sayoki G M Mfinanga; Odd Mørkve; Lisbet Sviland
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

7.  Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.

Authors:  H Yao; E Song; J Chen; P Hamar
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

8.  The role of apoptosis in the pathology of pancreatic cancer.

Authors:  Nicole Samm; Kristin Werner; Felix Rückert; Hans Detlev Saeger; Robert Grützmann; Christian Pilarsky
Journal:  Cancers (Basel)       Date:  2010-12-23       Impact factor: 6.639

9.  Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.

Authors:  Howard L Kaufman; Seunghee Kim-Schulze; Kelledy Manson; Gail DeRaffele; Josephine Mitcham; Kang Seok Seo; Dae Won Kim; John Marshall
Journal:  J Transl Med       Date:  2007-11-26       Impact factor: 5.531

10.  Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.

Authors:  Oliver F Bathe; Nava Dalyot-Herman; Thomas R Malek
Journal:  BMC Cancer       Date:  2003-07-28       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.